Loading
A phase 3 trial of Ifinatamab deruxtecan, Docetaxel, Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) is a phase 3 interventional study registered as NCT06925737 by Merck Sharp & Dohme LLC, with 1440 participants planned, started 2025-05-13 and due to reach its primary completion in 2028-06-26. Interventions recorded: Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication. Conditions listed: Prostate Cancer, Prostatic Neoplasms. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD).
Shares Ifinatamab deruxtecan, Docetaxel, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Prednisone, Docetaxel, Metastatic castration-resistant prostate cancer, Cytotoxic chemotherapy.
Shares Prednisone, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD).
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Metastatic castration-resistant prostate cancer, Antibody-drug conjugate (ADC), Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/